TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TENX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/25	05:31	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/22	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/22	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/15	05:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/14	22:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/05/14	21:00	GlobeNewswire Inc.	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	NASDAQ:TENX	Tenax Therapeutics Inc
2024/04/30	20:30	GlobeNewswire Inc.	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
2024/04/09	21:30	GlobeNewswire Inc.	Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	NASDAQ:TENX	Tenax Therapeutics Inc
2024/03/28	21:30	GlobeNewswire Inc.	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	NASDAQ:TENX	Tenax Therapeutics Inc
2024/03/12	21:30	GlobeNewswire Inc.	Tenax Therapeutics to Present at the 36th Annual Roth Conference	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/29	23:00	GlobeNewswire Inc.	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/27	06:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/27	06:31	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/24	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/22	06:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/22	06:30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/21	06:01	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/20	22:33	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/20	22:30	GlobeNewswire Inc.	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/17	01:28	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/16	09:36	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/15	04:58	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/14	06:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/13	06:46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/10	07:00	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/09	06:51	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	22:16	GlobeNewswire Inc.	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/08	10:01	GlobeNewswire Inc.	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	NASDAQ:TENX	Tenax Therapeutics Inc
2024/02/06	23:20	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:TENX	Tenax Therapeutics Inc